Literature DB >> 24190226

Hypertension exacerbates liver injury and hepatic fibrosis induced by a choline-deficient L-amino acid-defined diet in rats.

Shiho Arima1, Hirofumi Uto, Rie Ibusuki, Ryo Kumamoto, Shirou Tanoue, Seiichi Mawatari, Kohei Oda, Masatsugu Numata, Hiroshi Fujita, Makoto Oketani, Akio Ido, Hirohito Tsubouchi.   

Abstract

The effect of hypertension on non-alcoholic fatty liver disease (NAFLD) remains unclear at the molecular level. In this study, we investigated the effects of hypertension on the degree of hepatic steatosis, liver injury and hepatic fibrosis induced by a choline-deficient L-amino acid-defined (CDAA) diet in spontaneously hypertensive rats (SHRs). Seven-week-old male SHRs were fed standard chow with high or normal salt concentrations for 7 weeks, followed by a CDAA diet containing high or normal salt for an additional 8 or 24 weeks. Hepatic steatosis was assessed using hepatic triglyceride levels and Oil red O staining. Hepatic fibrosis was evaluated using Sirius red and Azan staining. Systolic blood pressure (SBP) gradually increased with a high-salt diet and was significantly higher after 7 weeks of feeding with high-salt vs. normal-salt chow. After 8 weeks on the CDAA diet, the degree of hepatic steatosis did not differ between the high-salt and normal-salt groups; however, alanine aminotransferase and fasting blood glucose levels were significantly higher and hepatic mRNA levels for interleukin (IL)-10 and heme oxygenase (HO)-1 were significantly lower in the high-salt group compared with the normal-salt group. After 24 weeks on the CDAA diet, the high-salt group had significantly more severe hepatic fibrosis and a higher hepatic mRNA expression of α-smooth muscle actin and lower hepatic IL-10 and HO-1 mRNA levels compared with the normal-salt group. In conclusion, our results indicate that hypertension is a potential risk factor for liver injury and hepatic fibrosis through glucose intolerance and decreased IL-10-mediated or HO-1-induced anti-inflammatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24190226     DOI: 10.3892/ijmm.2013.1544

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  12 in total

Review 1.  Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease.

Authors:  Frank T Spradley; Jillian A Smith; Barbara T Alexander; Christopher D Anderson
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-03-06       Impact factor: 4.310

2.  Effects of primary hypertension treatment in the oncological outcomes of hepatocellular carcinoma.

Authors:  Victor Lopez-Lopez; Alvaro Gomez Ruiz; Asunción Lopez-Conesa; Roberto Brusadin; Valentin Cayuela; Albert Caballero-Illanes; Máximo Torres; Ricardo Robles Campos
Journal:  Ann Transl Med       Date:  2020-07

3.  The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study.

Authors:  Yuri Cho; Eun Ju Cho; Jeong-Ju Yoo; Young Chang; Goh Eun Chung; In Young Choi; Sang-Hyun Park; Kyungdo Han; Yoon Jun Kim; Jung-Hwan Yoon; Dong Wook Shin; Su Jong Yu
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

4.  Intestinal Gastrin/CCKBR (Cholecystokinin B Receptor) Ameliorates Salt-Sensitive Hypertension by Inhibiting Intestinal Na+/H+ Exchanger 3 Activity Through a PKC (Protein Kinase C)-Mediated NHERF1 and NHERF2 Pathway.

Authors:  Xiaoliang Jiang; Yunpeng Liu; Xin-Yang Zhang; Xue Liu; Xing Liu; Xianxian Wu; Pedro A Jose; Shun Duan; Fu-Jian Xu; Zhiwei Yang
Journal:  Hypertension       Date:  2022-06-08       Impact factor: 9.897

5.  High-salt in addition to high-fat diet may enhance inflammation and fibrosis in liver steatosis induced by oxidative stress and dyslipidemia in mice.

Authors:  Yuzaburo Uetake; Hitoshi Ikeda; Rie Irie; Kazuaki Tejima; Hiromitsu Matsui; Sayoko Ogura; Hong Wang; ShengYu Mu; Daigoro Hirohama; Katsuyuki Ando; Tatsuya Sawamura; Yutaka Yatomi; Toshiro Fujita; Tatsuo Shimosawa
Journal:  Lipids Health Dis       Date:  2015-02-13       Impact factor: 3.876

6.  High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China.

Authors:  Xinyan Yu; Chen Chen; Yi Guo; Yuling Tong; Yi Zhao; Lingyan Wu; Xue Sun; Xifeng Wu; Zhenya Song
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

7.  Exploring Interactions between Primary Hepatocytes and Non-Parenchymal Cells on Physiological and Pathological Liver Stiffness.

Authors:  Vaishaali Natarajan; Youra Moeun; Srivatsan Kidambi
Journal:  Biology (Basel)       Date:  2021-05-05

8.  Salt-Responsive Metabolite, β-Hydroxybutyrate, Attenuates Hypertension.

Authors:  Saroj Chakraborty; Sarah Galla; Xi Cheng; Ji-Youn Yeo; Blair Mell; Vishal Singh; BengSan Yeoh; Piu Saha; Anna V Mathew; Matam Vijay-Kumar; Bina Joe
Journal:  Cell Rep       Date:  2018-10-16       Impact factor: 9.423

9.  TBH score: a new model to predict and prevent severe liver damage after chemotherapy for cancer patients.

Authors:  Mengping Zhang; Yong Bao; Wei Chen; Mengchao Wei; Hui Pang; Yu Feng Ren; Jie Mei; Sheng Ye; Shunjun Fu; Zhen Wei Peng
Journal:  Cancer Manag Res       Date:  2019-07-11       Impact factor: 3.989

10.  Blood Test Results of Pregnant COVID-19 Patients: An Updated Case-Control Study.

Authors:  Guoqiang Sun; Yizhi Zhang; Qing Liao; Yao Cheng
Journal:  Front Cell Infect Microbiol       Date:  2020-10-07       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.